Council Implementing Decision (EU) 2015/1873 of 8 October 2015 on subjecting 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-DMAR) and 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45) to control measures

to subject 4-methyl-5-(4methylphenyl)-4,5-dihydrooxazol-2-amine (4,4'-DMAR) and 1-cyclohexyl-4(1,2-diphenylethyl)piperazine (MT-45) to control measures. ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion. BACKGROUND: in compliance with Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) assessed the risks on the new psychoactive substance 4,4'-DMAR and MT-45 . The risk assessment reports were submitted to the Commission and to the Council on 19 September 2014. (1) 4,4'-DMAR is a synthetic substituted oxazoline derivative. It is a derivative of aminorex and 4-methylaminorex (4-MAR), two synthetic stimulants controlled under the 1971 United Nations Convention on Psychotropic Substances. The Committee on Civil Liberties, Justice and Home Affairs adopted the report by Michał BONI (EPP, PL) on the draft Council implementing decision on subjecting 4-methyl-5-(4methylphenyl)-4,5-dihydrooxazol-2-amine (4,4'-DMAR) and 1-cyclohexyl-4(1,2-diphenylethyl)piperazine (MT-45) to control measures. The committee approved the Council draft which seeks to invite the Member States to subject 4,4'-DMAR and MT-45 to control measures. In compliance with Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) assessed the risks on the new psychoactive substances. The risk assessment report was subsequently submitted to the Commission and to the Council on 19 September 2014. The European Parliament adopted by 650 votes to 5, with 33 abstentions, a legislative resolution on the draft Council implementing decision on subjecting 4-methyl-5-(4methylphenyl)-4,5-dihydrooxazol-2-amine (4,4'-DMAR) and 1-cyclohexyl-4(1,2-diphenylethyl)piperazine (MT-45) to control measures. In line with the Committee on Civil Liberties, Justice and Home Affairs, the European Parliament approved the Council draft aiming to subject 4,4'-DMAR and MT-45 to control measures. NON-LEGISLATIVE ACT: Council Implementing Decision (EU) 2015/1873 on subjecting 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-DMAR) and 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45) to control measures. CONTENT: the Council adopted an implementing decision on subjecting the new psychoactive substance 4-methyl-5-(4methylphenyl)-4,5-dihydrooxazol-2-amine (4,4'-DMAR) and 1-cyclohexyl-4(1,2-diphenylethyl)piperazine (MT-45) to control measures across the Union: 4,4′-DMAR , a synthetic substituted oxazoline derivative, sold and consumed as a substance on its own, but it has also been mis-sold on the illicit market as ecstasy and amphetamines; MT-45 is one of a series of 1-(1,2-diphenylethyl)piperazine analgesics invented in the early 1970s and has been present on the drugs market in the Union since October 2013. The implementing Decision implements Decision 2005/387/JHA that confers upon…

Official title: Council Implementing Decision (EU) 2015/1873 of 8 October 2015 on subjecting 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-DMAR) and 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45) to control measures

Summary extracted from the European Parliament's own per-stage procedure record. Data © European Union (Decision 2011/833/EU). Methodology.